P21 Peptide (P021): CNTF-Derived Neurogenesis and Cognition Research
P21 (P021) is a small synthetic peptide built to capture the brain-boosting side of a natural growth factor, CNTF, while dropping its appetite-suppressing side. This research-use-only reference explains how P21 was designed, how it promotes hippocampal neurogenesis and raises BDNF, what it did in Alzheimer's-model mice, and the honest limit that all of it comes from a single research group.
Research-use-only disclaimer: P21 (P021) supplied as a research chemical is intended strictly for in-vitro and laboratory research use and is not intended for human or veterinary use in that context. Every finding below is drawn from cell-culture or animal models and is described in hedged, mechanistic terms. Nothing here is medical advice.
TL;DR
P21 (P021) is a synthetic CNTF-derived neurotrophic peptide from Khalid Iqbal's laboratory, built from an 11-residue active region of ciliary neurotrophic factor with an adamantane group for blood-brain-barrier entry. In research models it promotes dentate-gyrus neurogenesis, raises BDNF, lowers tau hyperphosphorylation, and rescues memory in Alzheimer's-model mice. All evidence is preclinical and from one group. Research use only.
Origin: derived from an active region of CNTF; developed by Khalid Iqbal's laboratory.
Design: 11-residue sequence with an adamantane modification for BBB entry and stability.
Effects: hippocampal neurogenesis, increased BDNF, reduced tau hyperphosphorylation.
Alzheimer models: rescued memory and reduced tangle pathology, even after disease onset.
Caveat: evidence is preclinical and from a single group; no human trials. Research use only.
What Is P21 (P021)?
P21, usually written P021, is a small synthetic neurotrophic peptide. It was developed by the laboratory of Khalid Iqbal at the New York State Institute for Basic Research in Developmental Disabilities, with Inge Grundke-Iqbal among the collaborators.[1] It belongs to the neuro-research family alongside Semax and Dihexa.
How Was P21 Designed from CNTF?
Ciliary neurotrophic factor (CNTF) supports neuron survival and neurogenesis, but as a drug it has a serious drawback: it suppresses appetite by activating hypothalamic STAT3. The Iqbal group set out to keep the pro-neurogenic activity and drop the appetite effect. They identified an 11-amino-acid sequence from a biologically active region of CNTF and added an adamantane group to a key glycine to help the peptide cross the blood-brain barrier and resist enzymatic breakdown.[1] The result is a small, brain-penetrant compound that mimics part of CNTF's signaling.
Does P21 Promote Neurogenesis and Raise BDNF?
In research models, yes. P21 promotes the birth of new neurons in the hippocampal dentate gyrus, the region most associated with adult neurogenesis and memory, and it increases expression of brain-derived neurotrophic factor (BDNF).[1]
What Did the Alzheimer's-Model Studies Show?
P021 was tested in transgenic Alzheimer's disease mouse models, including a therapeutic paradigm where it was given after disease was established. In those studies it rescued spatial memory deficits, reduced neurofibrillary tangle (tau) pathology, and increased hippocampal neurogenesis.[2] Rescuing memory after onset, rather than only preventing it, is what made these results notable in the tauopathy literature.
What Has Research NOT Established?
The central limit is easy to state: the entire P21 evidence base comes from a single research group, and there are no human trials.[2] Promising, reproducible-within-one-lab animal data is not the same as independently replicated or clinical proof. For a research audience, P21 is a well-characterized CNTF-mimetic tool for neurogenesis and tau studies, with independent replication and human translation both still open.
| Property | Detail |
|---|---|
| Origin | Active region of CNTF; Iqbal laboratory |
| Design | 11-residue peptide with adamantane group for BBB entry/stability |
| Neurogenesis | Increased in hippocampal dentate gyrus |
| Signals | Higher BDNF; lower tau hyperphosphorylation |
| Alzheimer models | Rescued memory; reduced tangle pathology |
| Evidence caveat | Single group; no human trials; preclinical only |
How is research-grade P21 characterized?
P21's adamantane modification makes identity confirmation important. Research-grade P21 is typically verified by reversed-phase HPLC for purity and mass spectrometry for identity, handled cold, and supplied for laboratory use only. At PrymaLab, research peptides are characterized with HPLC/MS verification and independent third-party testing. No specific lot data are asserted in this general reference.
Frequently Asked Questions
What is P21 (P021)?
A small synthetic neurotrophic peptide derived from a region of CNTF (developed by Khalid Iqbal's lab), engineered with an adamantane group for blood-brain-barrier entry, studied for neurogenesis and cognition in animal models.
How does P21 work?
It mimics part of CNTF signaling to promote hippocampal neurogenesis, raise BDNF, and reduce tau hyperphosphorylation, without CNTF's appetite-suppressing effect.
Is P21 proven in humans?
No. The evidence is preclinical and comes from a single research group; there are no human trials and no independent replication yet.
Is P21 approved for human use?
No. P21 reference material is for laboratory research only and is not a drug or treatment.
References
- Kazim SF, Iqbal K. Neurotrophic factor small-molecule peptide mimetic P021 and neurodegeneration: design and mechanism. Mol Neurodegener / related reports.
- Prevention of dendritic and synaptic deficits and cognitive impairment with the neurotrophic compound P021 (3xTg-AD and related Alzheimer models). PMC. PMC5488423
- Effects of a CNTF small-molecule peptide mimetic (P021) in models of neurodevelopmental and neurodegenerative disorders. PMC. PMC11590213
Final disclaimer: This article is an educational research reference. P21 (P021) is sold and studied for laboratory research use only and is not approved by any regulatory authority for human or veterinary use. Statements have not been evaluated by the FDA. Nothing here should be interpreted as medical advice or a treatment claim for any disease.
Mechanistic descriptions are observations from cell and animal models from a single research group that may not generalize or replicate. Always verify the legal status of any research compound in your jurisdiction before purchase or use.
